Safoora Pordel
Overview
Explore the profile of Safoora Pordel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haghnavaz N, Rezaee M, Pordel S, Shobeiri S, Dashti M, Ansari B, et al.
Immunopharmacol Immunotoxicol
. 2024 Oct;
46(6):815-828.
PMID: 39376102
Objective: One of the most effective treatments for allergic respiratory diseases is allergen-specific sublingual immunotherapy (SLIT). While, mannose targeting has been applied in various immunostimulatory approaches, but it has not...
2.
Emami Z, Shobeiri S, Khorrami R, Haghnavaz N, Rezaee M, Moghadam M, et al.
Mediators Inflamm
. 2024 Jul;
2024:5821996.
PMID: 39045230
Background: Psoriasis is a noncontagious auto-inflammatory chronic skin disease. So far, some of the inflammatory genes were upregulated in mouse model of psoriasis. This study examined changes in skin mRNA...
3.
Ansari B, Abbaspour M, Estajy A, Haghnavaz N, Pordel S, Rezaee M, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2024 May;
397(10):7839-7856.
PMID: 38743115
Curcumin (CUR) has been considered a potential therapeutic agent for allergic reactions due to its antioxidant and anti-inflammatory activities. Nanofibers have attracted increasing attention in drug delivery. The aim of...
4.
Pordel S, McCloskey A, Almahmeed W, Sahebkar A
Pharmacol Rep
. 2024 Mar;
76(2):235-250.
PMID: 38448729
Traumatic brain injury (TBI), often referred to as the "silent epidemic", is the most common cause of mortality and morbidity worldwide among all trauma-related injuries. It is associated with considerable...
5.
Pordel S, Rezaee M, Moghadam M, Sankian M
Immunol Invest
. 2024 Jan;
53(3):523-539.
PMID: 38166585
Background: The rapid uptake of antigens by antigen-presenting cells (APCs) and their migration to draining lymph nodes in the initial hours after antigen administration in epicutaneous allergen specific immunotherapy (EPIT)...
6.
Pordel S, Haghnavaz N, Rezaee M, Shobeiri S, Ansari B, Dashti M, et al.
Immunol Res
. 2023 Dec;
72(3):460-475.
PMID: 38091227
Background: Gold nanoparticles (GNPs) have previously been suggested as appropriate carriers for allergen-specific immunotherapy (AIT). In this study, we assessed efficacy of GNPs and dendritic cells (DC)-specific aptamer-modified GNPs (Apts-GNP)...
7.
Shobeiri S, Dashti M, Pordel S, Rezaee M, Haghnavaz N, Moghadam M, et al.
Cytokine
. 2023 Oct;
172:156406.
PMID: 37879125
Background: Tumor Necrosis Factor-α (TNF-α) is a pro-inflammatory factor that plays a pivotal role in psoriasis. Due to limitations of monoclonal antibody-based therapies, it is needed to discover new anti-TNF-α...
8.
Pordel S, Khorrami M, Saadatpour F, Rezaee D, Cho W, Jahani S, et al.
Pathol Res Pract
. 2023 Aug;
249:154729.
PMID: 37639952
MicroRNAs (miRNAs) are a widely-studied class of non-coding RNAs characterized by their short length (18-25 nucleotides). The precise functions of miRNAs are not well-elucidated; however, an increasing number of studies...
9.
Adabi N, Pordel S, Rezaee M, Shobeiri F, Shobeiri S
J Gene Med
. 2023 Feb;
25(5):e3484.
PMID: 36781390
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy approach that has played a tremendous role in the battle against cancer for years. Since the CAR T lymphocytes are unrestricted-major...
10.
Najafi S, Zarch S, Majidpoor J, Pordel S, Aghamiri S, Rasul M, et al.
Int J Biol Macromol
. 2022 Nov;
225:1038-1048.
PMID: 36410538
Circular RNAs (circRNAs) are a novel class of non-coding RNAs. They are single-stranded RNA transcripts characterized with a closed loop structure making them resistant to degrading enzymes. Recently, circRNAs have...